277 related articles for article (PubMed ID: 32586587)
1. Post-Discharge Prophylaxis With Rivaroxaban Reduces Fatal and Major Thromboembolic Events in Medically Ill Patients.
Spyropoulos AC; Ageno W; Albers GW; Elliott CG; Halperin JL; Hiatt WR; Maynard GA; Steg PG; Weitz JI; Lu W; Spiro TE; Barnathan ES; Raskob GE
J Am Coll Cardiol; 2020 Jun; 75(25):3140-3147. PubMed ID: 32586587
[TBL] [Abstract][Full Text] [Related]
2. Rivaroxaban for Thromboprophylaxis after Hospitalization for Medical Illness.
Spyropoulos AC; Ageno W; Albers GW; Elliott CG; Halperin JL; Hiatt WR; Maynard GA; Steg PG; Weitz JI; Suh E; Spiro TE; Barnathan ES; Raskob GE;
N Engl J Med; 2018 Sep; 379(12):1118-1127. PubMed ID: 30145946
[TBL] [Abstract][Full Text] [Related]
3. Benefit-Risk of Rivaroxaban for Extended Thromboprophylaxis After Hospitalization for Medical Illness: Pooled Analysis From MAGELLAN and MARINER.
Raskob GE; Spyropoulos AC; Spiro TE; Lu W; Yuan Z; Levitan B; Suh E; Barnathan ES
J Am Heart Assoc; 2021 Nov; 10(22):e021579. PubMed ID: 34755519
[TBL] [Abstract][Full Text] [Related]
4. The MARINER trial of rivaroxaban after hospital discharge for medical patients at high risk of VTE. Design, rationale, and clinical implications.
Raskob GE; Spyropoulos AC; Zrubek J; Ageno W; Albers G; Elliott CG; Halperin J; Haskell L; Hiatt WR; Maynard GA; Peters G; Spiro T; Steg PG; Suh EY; Weitz JI
Thromb Haemost; 2016 Jun; 115(6):1240-8. PubMed ID: 26842902
[TBL] [Abstract][Full Text] [Related]
5. Benefit-Risk Assessment of Rivaroxaban for Extended Thromboprophylaxis After Hospitalization for Medical Illness.
Raskob GE; Ageno W; Albers G; Elliott CG; Halperin J; Maynard G; Steg PG; Weitz JI; Albanese J; Yuan Z; Levitan B; Lu W; Suh EY; Spiro T; Lipardi C; Barnathan ES; Spyropoulos AC
J Am Heart Assoc; 2022 Oct; 11(20):e026229. PubMed ID: 36205248
[TBL] [Abstract][Full Text] [Related]
6. Comparison of Fatal or Irreversible Events With Extended-Duration Betrixaban Versus Standard Dose Enoxaparin in Acutely Ill Medical Patients: An APEX Trial Substudy.
Gibson CM; Korjian S; Chi G; Daaboul Y; Jain P; Arbetter D; Goldhaber SZ; Hull R; Hernandez AF; Lopes RD; Gold A; Cohen AT; Harrington RA;
J Am Heart Assoc; 2017 Jul; 6(7):. PubMed ID: 28698258
[TBL] [Abstract][Full Text] [Related]
7. Rivaroxaban for thromboprophylaxis among patients recently hospitalized for acute infectious diseases: a subgroup analysis of the MAGELLAN study.
Cohoon KP; De Sanctis Y; Haskell L; McBane RD; Spiro TE
J Thromb Haemost; 2018 Jul; 16(7):1278-1287. PubMed ID: 29753308
[TBL] [Abstract][Full Text] [Related]
8. Extended Venous Thromboembolism Prophylaxis in Medically Ill Patients: An NATF Anticoagulation Action Initiative.
Barkoudah E; Piazza G; Hecht TEH; Grant P; Deitelzweig S; Fang MC; Fanikos J; Kao CK; Barnes GD; Chen T; Ramishvili T; Schnipper JL; Goldstein JN; Ruff CT; Kaatz S; Schwartz A; Connors JM; Goldhaber SZ
Am J Med; 2020 May; 133 Suppl 1():1-27. PubMed ID: 32362349
[TBL] [Abstract][Full Text] [Related]
9. Association of Bleeding Severity With Mortality in Extended Thromboprophylaxis of Medically Ill Patients in the MAGELLAN and MARINER Trials.
Spyropoulos AC; Raskob GE; Cohen AT; Ageno W; Weitz JI; Spiro TE; Lu W; Lipardi C; Albers GW; Elliott CG; Halperin JL; Hiatt WR; Maynard G; Steg PG; Sugarmann C; Barnathan ES
Circulation; 2022 May; 145(19):1471-1479. PubMed ID: 35389229
[TBL] [Abstract][Full Text] [Related]
10. Rivaroxaban for Preventing Venous Thromboembolism in High-Risk Ambulatory Patients with Cancer: Rationale and Design of the CASSINI Trial. Rationale and Design of the CASSINI Trial.
Khorana AA; Vadhan-Raj S; Kuderer NM; Wun T; Liebman H; Soff G; Belani C; O'Reilly EM; McBane R; Eikelboom J; Damaraju CV; Beyers K; Dietrich F; Kakkar AK; Riess H; Peixoto RD; Lyman GH
Thromb Haemost; 2017 Nov; 117(11):2135-2145. PubMed ID: 28933799
[TBL] [Abstract][Full Text] [Related]
11. Effect of extended-duration thromboprophylaxis on venous thromboembolism and major bleeding among acutely ill hospitalized medical patients: a bivariate analysis.
Chi G; Goldhaber SZ; Kittelson JM; Turpie AGG; Hernandez AF; Hull RD; Gold A; Curnutte JT; Cohen AT; Harrington RA; Gibson CM
J Thromb Haemost; 2017 Oct; 15(10):1913-1922. PubMed ID: 28762617
[TBL] [Abstract][Full Text] [Related]
12. Rivaroxaban or Aspirin for Extended Treatment of Venous Thromboembolism.
Weitz JI; Lensing AWA; Prins MH; Bauersachs R; Beyer-Westendorf J; Bounameaux H; Brighton TA; Cohen AT; Davidson BL; Decousus H; Freitas MCS; Holberg G; Kakkar AK; Haskell L; van Bellen B; Pap AF; Berkowitz SD; Verhamme P; Wells PS; Prandoni P;
N Engl J Med; 2017 Mar; 376(13):1211-1222. PubMed ID: 28316279
[TBL] [Abstract][Full Text] [Related]
13. Extended thromboprophylaxis in the acutely ill medical patient after hospitalization - a paradigm shift in post-discharge thromboprophylaxis.
Mahan CE; Burnett AE; Fletcher ML; Spyropoulos AC
Hosp Pract (1995); 2018 Feb; 46(1):5-15. PubMed ID: 29171776
[TBL] [Abstract][Full Text] [Related]
14. Rivaroxaban for extended thromboprophylaxis in acutely ill medical patients 75 years of age or older.
Ageno W; Lopes RD; Goldin M; Yusen RD; Albers GW; Elliott GC; Halperin JL; Hiatt WR; Maynard G; Steg PG; Weitz JI; Suh E; Lu W; Barnathan ES; Raskob GE; Spyropoulos AC
J Thromb Haemost; 2021 Nov; 19(11):2772-2780. PubMed ID: 34314574
[TBL] [Abstract][Full Text] [Related]
15. Rivaroxaban versus no anticoagulation for post-discharge thromboprophylaxis after hospitalisation for COVID-19 (MICHELLE): an open-label, multicentre, randomised, controlled trial.
Ramacciotti E; Barile Agati L; Calderaro D; Aguiar VCR; Spyropoulos AC; de Oliveira CCC; Lins Dos Santos J; Volpiani GG; Sobreira ML; Joviliano EE; Bohatch Júnior MS; da Fonseca BAL; Ribeiro MS; Dusilek C; Itinose K; Sanches SMV; de Almeida Araujo Ramos K; de Moraes NF; Tierno PFGMM; de Oliveira ALML; Tachibana A; Chate RC; Santos MVB; de Menezes Cavalcante BB; Moreira RCR; Chang C; Tafur A; Fareed J; Lopes RD;
Lancet; 2022 Jan; 399(10319):50-59. PubMed ID: 34921756
[TBL] [Abstract][Full Text] [Related]
16. Risk of Severe Bleeding With Extended Rivaroxaban to Prevent Venous Thromboembolism in Acute Medically Ill Patients With Bronchiectasis.
Lipardi C; Elliott CG; Sugarmann CL; Haskell L; Spyropoulos AC; Raskob GE; Xu J; Lu W; Marsigliano J; Spiro T; Yuan Z; Wu S; Barnathan ES
Clin Appl Thromb Hemost; 2021; 27():10760296211053316. PubMed ID: 34719984
[No Abstract] [Full Text] [Related]
17. Medically Ill hospitalized Patients for COVID-19 THrombosis Extended ProphyLaxis with rivaroxaban ThErapy: Rationale and Design of the MICHELLE Trial.
Ramacciotti E; Agati LB; Calderaro D; Volpiani GG; de Oliveira CCC; Aguiar VCR; Rodrigues E; Sobreira ML; Joviliano EE; Dusilek C; Itinose K; Dedivitis RA; Cortina AS; Sanches SMV; de Moraes NF; Tierno PFGMM; de Oliveira ALML; Tachibana A; Chate RC; Santos MVB; Cavalcante BBM; Moreira RCR; Chiann C; Tafur A; Spyropoulos AC; Lopes RD
Am Heart J; 2021 Dec; 242():115-122. PubMed ID: 34480880
[TBL] [Abstract][Full Text] [Related]
18. Retrospective Evaluation of Postoperative Adverse Drug Events in Patients Receiving Rivaroxaban After Major Orthopedic Surgery Compared with Standard Therapy in a Community Hospital.
Cieri NE; Kusmierski K; Lackie C; Van Opdorp A; Hassan AK
Pharmacotherapy; 2017 Feb; 37(2):170-176. PubMed ID: 28028830
[TBL] [Abstract][Full Text] [Related]
19. Extended prophylaxis for venous thromboembolism after hospitalization for medical illness: A trial sequential and cumulative meta-analysis.
Bajaj NS; Vaduganathan M; Qamar A; Gupta K; Gupta A; Golwala H; Butler J; Goldhaber SZ; Mehra MR
PLoS Med; 2019 Apr; 16(4):e1002797. PubMed ID: 31034476
[TBL] [Abstract][Full Text] [Related]
20. Rivaroxaban for thromboprophylaxis in acutely ill medical patients.
Cohen AT; Spiro TE; Büller HR; Haskell L; Hu D; Hull R; Mebazaa A; Merli G; Schellong S; Spyropoulos AC; Tapson V;
N Engl J Med; 2013 Feb; 368(6):513-23. PubMed ID: 23388003
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
